Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 134 posts
October 9, 2017 | Blogs
As a class, manufacturers of PDxs (PD1s / PD-L1) are enjoying great success when it comes to marketing authorisation, with four of the five brands achieving multiple FDA and EMA approvals. CBPartners takes a closer look at the successes and failures in this highly competitive class of drugs.
October 4, 2017 | Blogs
Rome Wasn’t Built in a Day Either: Greece is Back Again with New Pricing and Reimbursement Policy Reforms
CBPartners explores the new pricing and reimbursement policy reforms in Greece.
September 17, 2017 | Blogs
Yet another drug pricing debate has started to brew in the USA, with its epicentre right in DC. Two Democratic members of the US House (Elijah Cummings (D-MD) and Peter Welch (D-VT)), announced that they are launching an investigation into the pricing of disease-modifying treatments for multiple sclerosis (MS). CBPartners investigates MS pricing in the political context.
August 18, 2017 | Blogs
In April 2017, AIFA (Agenzia Italiana del Farmaco, Italian Medicines Agency) released a new algorithm to assess and evaluate the level of innovativeness of new drugs aimed to get reimbursement by the SSN (Sistema Sanitario Nazionale, National Health System) through the EUR 1 billion fund made available by the Italian MoH (Ministero della Salute, Ministry of Health) for innovative therapies. CBPartners investigates the impact that this has.